Live Biotherapeutic Products (LBPs) hold considerable promise for the treatment of several disease indications. Before the promise of LBPs can be delivered, several hurdles including appropriate analysis methods for CMC have to be considered. Yvonne Nyavor, Principal Scientist at Boston Analytics, discussed during the Microbiome Connect: USA 2022 the improvement of analysis methods for LBPs, presenting both old and new techniques for appropriately analyzing LBPs from quality perspective.
- HCP Area
- Probiotic databases